We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+3.23%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$472B
AUM Growth
+$3.53B
Cap. Flow
-$5.2B
Cap. Flow %
-1.1%
Top 10 Hldgs %
16.24%
Holding
2,596
New
95
Increased
1,094
Reduced
954
Closed
84

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.2B
2
AGN
Allergan plc
AGN
+$1.03B
3
GILD icon
Gilead Sciences
GILD
+$917M
4
PFE icon
Pfizer
PFE
+$901M
5
NKE icon
Nike
NKE
+$872M

Sector Composition

Rank Sector Weight
1 Healthcare 19.88%
2 Consumer Discretionary 14.86%
3 Financials 14.2%
4 Technology 12.51%
5 Industrials 9.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HBP
2426
DELISTED
Huttig Building Products, Inc.
HBP
$91K ﹤0.01%
17,350
+2,200
+15% +$10.4K
ARNA
2427
DELISTED
Arena Pharmaceuticals Inc
ARNA
$89K ﹤0.01%
5,230
COWN
2428
DELISTED
Cowen Inc. Class A Common Stock
COWN
$89K ﹤0.01%
7,500
PHLT
2429
DELISTED
Performant Healthcare Inc
PHLT
$87K ﹤0.01%
53,900
CJES
2430
DELISTED
C&J ENERGY SVCS LTD
CJES
$87K ﹤0.01%
145,200
+112,400
+343% +$105K
PZN
2431
DELISTED
Pzena Investment Management, Inc. Class A
PZN
$86K ﹤0.01%
11,300
-343,600
-97% -$2.92M
WMAR
2432
DELISTED
West Marine Inc
WMAR
$85K ﹤0.01%
10,100
JIVE
2433
DELISTED
Jive Software, Inc.
JIVE
$85K ﹤0.01%
22,600
FDML
2434
DELISTED
Federal-Mogul Holdings Corporation
FDML
$84K ﹤0.01%
10,100
SOHO
2435
DELISTED
Sotherly Hotels
SOHO
$82K ﹤0.01%
14,600
CRDF icon
2436
Cardiff Oncology
CRDF
$79.4M
$81K ﹤0.01%
+247
New +$85.1K
HBIO icon
2437
Harvard Bioscience
HBIO
$28.4M
$81K ﹤0.01%
2,820
-10
-0.4% -$318
ENT
2438
DELISTED
Global Eagle Entertainment Inc.
ENT
$81K ﹤0.01%
488
NMBL
2439
DELISTED
Nimble Storage, Inc.
NMBL
$81K ﹤0.01%
10,200
-106,800
-91% -$831K
ENZ
2440
DELISTED
Enzo Biochem, Inc.
ENZ
$78K ﹤0.01%
13,100
RFP
2441
DELISTED
Resolute Forest Products Inc.
RFP
$77K ﹤0.01%
14,600
IMMU
2442
DELISTED
Immunomedics Inc
IMMU
$77K ﹤0.01%
33,100
AIOT
2443
PowerFleet Inc
AIOT
$417M
$74K ﹤0.01%
15,300
GNRT
2444
DELISTED
Gener8 Maritime, Inc.
GNRT
$74K ﹤0.01%
11,600
TVIA
2445
DELISTED
TerraVia Holdings, Inc. Common Stock
TVIA
$74K ﹤0.01%
+28,200
New +$65.5K
BDSI
2446
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$74K ﹤0.01%
31,500
-100
-0.3% -$276
UCTT
2447
Ultra Clean Holdings
UCTT
$4.22B
$73K ﹤0.01%
12,800
NBSE
2448
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$73K ﹤0.01%
67
TTPH
2449
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$73K ﹤0.01%
845
+5
+0.6% +$458
KRO icon
2450
KRONOS Worldwide
KRO
$960M
$71K ﹤0.01%
13,500

Similar funds

T. Rowe Price Associates's Q2 2016 Portfolio in Review

As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.

  • T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
  • T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
  • T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
  • T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
  • T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
  • T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
  • T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.

Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.